

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**


**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

<b>Original Claim</b>	<b>New Claim</b>
1	43
2	44
3	45
4	46
5	47
6	48
7	49
8	50
9	51
10	52
11	53
12	54
13	55
14	56
25	57
28	58
29	59
30	60
31	61
32	62
33	63
34	64
35	65
36	66
37	67
38	68

Please amend the claims as follows:

Claims 1-42 cancelled.

43. (Currently Amended) A compound of formula I



I

or a pharmaceutically acceptable salt thereof wherein

Y is

- a) -NHC(=W)R<sup>1</sup>;
- b) -O-het, -S-het, or -NH-het;

X is -NR<sup>3</sup>-,

W is

- a) O, or
- b) S;

R<sup>1</sup> is

- a) H,
- b) C<sub>1-8</sub>alkyl,
- c) C<sub>3-6</sub>cycloalkyl,
- d) OC<sub>1-4</sub> alkyl,
- e) SC<sub>1-4</sub> alkyl,
- f) NH<sub>2</sub>,
- g) NHC<sub>1-6</sub> alkyl, or
- h) N(C<sub>1-6</sub> alkyl)<sub>2</sub>;

R<sup>2</sup> is

- a) H,
- b) halo, or
- c) C<sub>1-4</sub> alkyl;

R<sup>3</sup> is

- a) H,
- b) C<sub>1-8</sub>alkyl,

- c) aryl,
- d)  $C(=W)R^5$ ,
- e)  $C(=O)OR^6$ , or
- f)  $S(=O)_iR^7$ ;

$R^4$  is

- a) H, or
- b)  $C_{1-8}$ alkyl;

$R^5$  is

- a) H,
- b) aryl,
- c)  $NR^8R^9$ , or
- d)  $C_{1-8}$ alkyl;

$R^6$  is

- a)  $C_{1-8}$ alkyl,
- b) aryl, or

$R^7$  is

- a) aryl,
- b)  $NR^8R^9$ , or
- c)  $C_{1-8}$ alkyl;

$R^8$  and  $R^9$  are independently

- a) H,
- b)  $C_{1-8}$ alkyl, or
- c) aryl;

wherein  $>G-E-$  is  $>N-C-$  and Q is a carbon atom;

aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;

het is a C-linked five- (5) or six- (6) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring;

at each occurrence, alkyl or cycloalkyl is optionally substituted with one or more  $OR^8$ , halo, aryl,  $S(=O)_iR^7$ ,  $C(=W)R^8$ ,  $OC(=O)C_{1-6}$ alkyl, or  $NR^8R^9$ ;

at each occurrence, aryl is optionally substituted with one or more halo, OH,  $CF_3$ ,  $OC_{1-6}$ alkyl, CN,  $C_{1-6}$ alkyl,  $S(=O)_iR^7$ ,  $C(=W)R^8$ ,  $OC(=O)R^8$ ,  $NHC(=O)R^8$ , or  $NR^8R^9$ ;

- c) aryl,
- d) C(=W)R<sup>5</sup>,
- e) C(=O)OR<sup>6</sup>, or
- f) S(=O)<sub>i</sub>R<sup>7</sup>;

R<sup>4</sup> is

- a) H, or
- b) C<sub>1-8</sub>alkyl;

R<sup>5</sup> is

- a) H,
- b) aryl,
- c) NR<sup>8</sup>R<sup>9</sup>, or
- d) C<sub>1-8</sub>alkyl;

R<sup>6</sup> is

- a) C<sub>1-8</sub>alkyl,
- b) aryl, or

R<sup>7</sup> is

- a) aryl,
- b) NR<sup>8</sup>R<sup>9</sup>, or
- c) C<sub>1-8</sub>alkyl;

R<sup>8</sup> and R<sup>9</sup> are independently

- a) H,
- b) C<sub>1-8</sub>alkyl, or
- c) aryl;

wherein >G-E- is >N-C- and Q is a carbon atom;

aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;


het is a C-linked five- (5) or six- (6) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring;

at each occurrence, alkyl or cycloalkyl is optionally substituted with one or more OR<sup>8</sup>, halo, aryl, S(=O)<sub>i</sub>R<sup>7</sup>, C(=W)R<sup>8</sup>, OC(=O)C<sub>1-6</sub>alkyl, or NR<sup>8</sup>R<sup>9</sup>;

at each occurrence, aryl is optionally substituted with one or more halo, OH, CF<sub>3</sub>, OC<sub>1-6</sub>alkyl, CN, C<sub>1-6</sub>alkyl, S(=O)<sub>i</sub>R<sup>7</sup>, C(=W)R<sup>8</sup>, OC(=O)R<sup>8</sup>, NHC(=O)R<sup>8</sup>, or NR<sup>8</sup>R<sup>9</sup>;

at each occurrence, het is optionally substituted with one or more halo, OH, CF<sub>3</sub>, OC<sub>1-6</sub>alkyl, CN, C<sub>1-6</sub>alkyl, S(=O)<sub>1</sub>R<sup>7</sup>, C(=W)R<sup>8</sup>, OC(=O)R<sup>8</sup>, NHC(=O)R<sup>8</sup>, or NR<sup>8</sup>R<sup>9</sup>, oxo, or oxime;  
m is 2;  
n is 2; and  
i is 0, 1, or 2.

44. A compound of claim 43 which is a compound of formula IA:



IA.


45. A compound of claim 44 wherein R<sup>2</sup> is H.
46. A compound of claim 44 wherein R<sup>1</sup> is C<sub>1-6</sub>alkyl.
47. A compound of claim 44 wherein R<sup>1</sup> is methyl.
48. A compound of claim 46 wherein X is NR<sup>3</sup>.
49. A compound of claim 46 wherein R<sup>3</sup> is C(=O)R<sup>5</sup>, or C(=O)OR<sup>5</sup>.
50. A compound of claim 48 wherein R<sup>3</sup> is C(=O)CH<sub>2</sub>OH.
51. A compound of claim 48 wherein R<sup>3</sup> is CHO.
52. A compound of claim 49 wherein R<sup>5</sup> is C<sub>1-4</sub>alkyl, optionally substituted with C(=O)C<sub>1-4</sub>alkyl, OC(=O)C<sub>1-4</sub>alkyl, C(=O)phenyl, or phenyl, wherein said phenyl is optionally substituted with I, or CF<sub>3</sub>.
53. A compound of claim 49 wherein R<sup>5</sup> is phenyl.

54. A compound of claim 48 wherein R<sup>3</sup> is C(=S)R<sup>5</sup>, wherein R<sup>5</sup> is aryl, alkyl or NR<sup>8</sup>R<sup>9</sup>, wherein R<sup>8</sup> and R<sup>9</sup> are independently H, C<sub>1-4</sub>alkyl or aryl.

55. A compound of claim 48 wherein R<sup>3</sup> is S(=O)<sub>i</sub>C<sub>1-4</sub>alkyl,

56. A compound of claim 48 wherein R<sup>3</sup> is H, C<sub>1-8</sub>alkyl, or aryl, .

57. A compound of claim 43 which is a compound of formula IB:



IB

wherein A is O, S or NH and het is isoxazol-3-yl, isoxazol-5-yl, 1,2,4-oxadiazol-3-yl, isothiazol-3-yl, 1,2,4-thiadiazol-3-yl or 1,2,5-thiadiazol-3-yl.

58. A method for treating microbial infections comprising: administering to a mammal in need thereof an effective amount of a compound of claim 43.

59. The method of claim 58 wherein said compound is administered orally, parenterally, transdermally, or topically.

60. The method of claim 58 wherein said compound is administered in an amount of from about 0.1 to about 150 mg/kg of body weight/day.

61. The method of claim 58 wherein said compound is administered in an amount of from about 3 to about 100 mg/kg of body weight/day.

62. The method of claim 58 wherein said infection is skin infection.

63. The method of claim 58 wherein the infection is eye infection.

Respectfully submitted,

John H. Engelmann

John H. Engelmann, Attorney  
Registration No. 28,075

Date: 03/19/04

Pharmacia & Upjohn Company  
Global Intellectual Property  
301 Henrietta Street  
Kalamazoo, Michigan 49001

Telephone No. (269) 833-2532 or (269) 833-9500  
Telefax No. (269) 833-8897 or (269) 833-2316